Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

y has also won support from the Duchenne Parents Association and continues to work with them to progress this program through pre-clinical evaluation, in addition to the ongoing support from Agentschap NL (formerly SenterNovem).

GDNF

AMT is conducting pre-clinical research and has successfully completed a proof of concept study in a disease model of Parkinson's disease in collaboration with the University of Lund, Sweden. Data generated for AMT by the University of Wisconsin (USA) in a further pilot study using large animals also showed effective delivery, distribution and expression at levels that are expected to correlate with clinical efficacy; overcoming these challenges is one of the major challenges to clinical development. Taken together, these positive data encourage us to continue with the development of GDNF gene therapy and to extend it to other neurodegenerative indications such as multiple system atrophy (MSA) and Huntington's disease.

Sanfilippo B

Under an agreement signed at the beginning of this year, AMT is collaborating with a consortium led by Institut Pasteur in the clinical development of a novel gene therapy to treat Sanfilippo B. This rare genetic disease affecting new-born children leads to progressive neuronal degeneration and death. There is no approved therapy currently available.

On behalf of the Consortium, Institut Pasteur will lead the development program and will also sponsor the initial Phase I/II clinical study. AMT will manufacture and supply the adeno-associated virus, serotype 5 (AAV5) gene therapy product to the Consortium. The overall manufacturing contract entails payments to AMT of € 1.8 million. If the Consortium successfully demonstrates proof of concept in the Phase I/II study, AMT will have an option to acquire full commercial rights for the program. The Phase I/II clinical study is scheduled to begin in 2012.

Other Research and Development

AMT has demonstrated the ad
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... 2015 Ale Gicqueau, Founder and President ... Clinical Affairs at Align Technology, on “ Conducting Postmarket ... ACRP 2015 Global Conference and Exhibition on April 25th ... , During the poster presentation, Ale Gicqueau and Victor ... a Postmarket Registry, the requirements and resources to conduct ...
(Date:3/25/2015)... -- Optimal Research, LLC has been nominated as a ... Clinical Site or Trial Network". This is ... as a nominee in this ViE award category at ... in 2014. The ViE awards were created to honor ... contributions of companies and individuals in the vaccine industry. ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... 1 clinical studies support advancement to Phase 2 -, ... polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) accepted ... Association for the Study of Liver Diseases,(AASLD, Oct. 31 ...
... Prescription for Progress, WATERBURY, Conn., Sept. 24 ... Genomas(R), a biomedical company advancing,DNA-guided medicine and personalized ... the Path to Personalized Health Care -- being,held ... is providing,continuing medical education credits for physicians attending ...
... Detecting deadly fumes in subways, toxic gases ... is becoming easier and more efficient with a ... improve the technique,s sensitivity, scientists must design better ... them. , Researchers at the University of Illinois, ...
Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care 2Killer pulses help characterize special surfaces 2
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... Researchers at the University of Liverpool have resolved the debate ... division in the body. Research findings, published ... studies on how scientists could manipulate this shut-down process to ... cells of the body and cause harm. Previous research ...
... end-Ordovician mass extinction, killing roughly 86% of all marine species, ... This marine catastrophe has previously been attributed to a cooling ... seen to grow on the South Pole, and to increased ... but from a hot to less hot greenhouse planet which ...
... of genetic heredity, remain enigmatic 130 years after their discovery ... Nature by the team of Edith Heard, PhD, ... University of Massachusetts Medical School (UMMS), reveals a new layer ... that chromosomes fold in a series of contiguous "yarns" that ...
Cached Biology News:Study resolves debate on human cell shut-down process 2Discovery reveals chromosomes organize into 'yarns' 2Discovery reveals chromosomes organize into 'yarns' 3
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Selective media for Salmonella...
... Laminin-Based 96-well Cell Invasion Assay is designed ... using laminin as a significant barrier to ... in vitro in a convenient, high-throughput, 96-well ... appropriate for all types of adherent cells ...
... General description: self locking design in ... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ...
Biology Products: